Navigation Links
Gellhorn Pessary

ProductsGellhorn Pessary
Company Mentor Corporation
Item Gellhorn Pessary
Features 
  • It is easy to insert and remove, and allows for self-care.
  • This device is also less likely to be expelled.
Description The Gellhorn Pessary is used for a second to third degree prolapse, or procidentia. It has drainage holes in its base and comes in nine sizes. The knob of the Gellhorn easily folds over for insertion, and once in place rests on the posterior vaginal wall
Info Mentor Corporation
Customer Service: (800) 525-0245
Web site: http://www.mentorcorp.com/index-us.htm

Related medicine products :

1. Ring Pessary
2. Oval Pessary
3. Shaatz Pessary
4. Mar-Land Pessary
5. Dish Pessary
6. Gehrung Pessary
7. Hodge Pessary
8. Cube Pessary
9. Donut Pessary
10. Incontinence Ring Silicone Flexible Pessary
11. Pessary Fitting Set
Liquid Assayed and Unassayed Multiqual Controls are comprehensive, liquid, human serum based chemistry controls, available in three levels.
Lyphochek Benzo/TCA Control Set B is ideal for monitoring HPLC methods for identification and quantitation of benzodiazepines and antidepressant drugs.
Lyphochek Whole Blood Metals Control contains the major heavy metals of toxicological and environmental importance for whole blood analysis.
Lyphochek Urine Metals Control incorporates two levels of critical trace elements, heavy metals and organic metabolites, and is ideal for environmental and industrial testing.
Medicine Products:
(Date:7/25/2008)... - 180-Days of Marketing Exclusivity Begins -,...- Watson,Pharmaceuticals, Inc. (NYSE: WPI ), a le...today that its subsidiary has commenced commercial...es USP product in the 40mg,strength from its Davie...ith the launch, Watson has 180 days of marketing e...
(Date:7/25/2008)...URG, Ill., July 25 /PRNewswire/ -- Sagent Pharmace...utical company, today announced that it,has launch...arrhythmic,indicated for the treatment and prophyl...ion and hemodynamically unstable ventricular,tachy... heart beat.,Sagent,s amiodarone HCl injection wil...
(Date:7/25/2008)...D, Calif., July 25 /PRNewswire/ -- AutoGenomics, I...on statement on Form S-1 with the,Securities and E...l public,offering of shares of its common stock. T... all of which are expected to be offered by,AutoGe..., have not yet been,determined., J.P. Morgan Secu...
(Date:7/25/2008)... New program delivers immediate cost...4-hour telephone access to language interpreters] ...multilingual solutions. , ...E® http://www.lle-inc.com/index.html [(Langu...er of interpretation, translation, and language in...
Breaking Medicine News(10 mins):Health News:Watson Launches Omeprazole Delayed-Release Capsules, 40MG 2Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 2Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 3Health News:AutoGenomics, Inc. Files Registration Statement for Initial Public Offering 2Health News:LLE Launches Over-the-Phone Interpretation OPI Easy Switch Program 2Health News:LLE Launches Over-the-Phone Interpretation OPI Easy Switch Program 3
...e improvement in patients who undergo yoga program...y proving the age-old belief about the interrelati...nsiderable improvement in the quality of life of t...ga program than those who do not. The study, prese...
...f Disease in Childhood says ‘Low birthweight babie...become hyperactive and with low attention spans’ a...ntion span, and impulsive behaviour characterise t...er, or HKD for short. It is one of the most common...
...ntification of a starter hormone responsible for i...moths//. The research was led by David Champlin, ...Maine, and assisted by students Paul Allee of Port...hree colleagues who are professors at the Universi...
...ologist and brain injury expert died on Wednesday ... standards to determine whether a patient was in a...his family the cause of death was complications of...rd had long been an advocate for the right of term...
Other Medicine News:Health News:Yoga Along with Treatment for Breast Cancer Improves Quality of Life 2Health News:Yoga Along with Treatment for Breast Cancer Improves Quality of Life 3Health News:Hormone Transforming Caterpillars to Moths Identified 2Health News:Renowned Doctor Passes Away 2
(Date:7/22/2008)...Latest awards under Therapeutics Development Initi...rations to 23; next deadline January 20,2009, NE... of its mission to,speed delivery of transformativ...he Michael J. Fox Foundation for Parkinson,s Resea...ix industry research teams. The awards,were grante...
(Date:7/22/2008)...wo Regimens Including Lantus(R) and Apidra(R) Resu... with Type 2 Diabetes, Whatever the Algorithm ....J., July 22 /- Results from the "Adj...Simple Algorithm to Carbohydrate,Counting for Adju...published in the American Diabetes Association,s (...
(Date:7/22/2008)... Developed and Validated by Columbia University Me...Proprietary MicroRNA Technology, The Test Differ... Lung Cancer (NSCLC), Classifying Squamous-Cell C... Percent and Specificity of 90 Percent,This is the...s, Sensitivity as Biomarkers for Accurate...
(Date:7/22/2008)...Pilot Study Suggests That Ekkyo,s New Approach of ...ally Improve Scar Healing Physiology, MARSEILLES,...nown as,Heatwave Technology) a photomedicine compa...ems for skin scar prevention and reduction, announ...in Lasers in Surgery and Medicine*,reporting the r...
Breaking Medicine Technology:Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 2Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 2Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 4First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 2First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 3First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 4First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 5Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine" 2Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine" 3Center for Poverty Research to study senior hunger in America 2387 1Center for Poverty Research to study senior hunger in America 2387 2Weight Loss Can Control Hypertension 2385 1Weight Loss Can Control Hypertension 2385 2Weight Loss Can Control Hypertension 2385 3National Trichotillomania Awareness Week Gives Help and Hope to Hair Pullers 2382 1National Trichotillomania Awareness Week Gives Help and Hope to Hair Pullers 2382 2Connecticut Bishops Back Down over Provision of Emergency Contraception 2379 1Connecticut Bishops Back Down over Provision of Emergency Contraception 2379 2
...mbination Therapy Significantly Decreased Tumor Bl...e Tumors -, LOS ANGELES and TUSTIN, Calif., April ...aceuticals, Inc. , a,clinical stage biopharmaceuti...ies for the treatment of cancer and hepatitis C,vi...cal data,presented at the Centennial Annual Meetin...
...GARY, April 17, 2007 /PRNewswire-FirstCall/ - Onco...a poster by Dr. Maureen,E. Lane et al. of , New Yo...ovirus and Gemcitabine in Ras-Mutated Human HCT116... the American,Association for Cancer Research (AAC...runs from April 14-18, 2007. , The researchers fou...
Other Medicine Technology:Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies 2Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies 3Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies 4Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies 5Oncolytics Biotech Inc. Research Collaborators Demonstrate,Reovirus/Gemcitabine Combination Has Synergistic Effect Against,Human Colon Cancer Cell Lines 2Oncolytics Biotech Inc. Research Collaborators Demonstrate,Reovirus/Gemcitabine Combination Has Synergistic Effect Against,Human Colon Cancer Cell Lines 3